Corbus Pharmaceuticals Holdings Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
57.21 M |
Public Float |
53.66 M |
Corbus Pharmaceuticals Holdings Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$1.19 |
Market Cap |
$440.87 M |
Shares Outstanding |
64.46 M |
Public Float |
59.12 M |
Address |
500 River Ridge Drive Norwood Massachusetts 02062 United States |
Employees | - |
Website | http://www.corbuspharma.com |
Updated | 07/08/2019 |
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. |